Clyde Biosciences

Clyde Biosciences is a leading specialist CRO focused on revolutionizing cardiac safety pharmacology and heart failure drug discovery through its unique CellOPTIQ® technology. Founded in 2013, the company has established itself as a key player in the adoption of New Approach Methodologies (NAMs), having completed over 300 client studies and collaborated extensively with the FDA, HESI, and top pharma on regulatory initiatives like CiPA. Its integrated assay platform enables faster, more accurate, and human-relevant cardiac functional data, helping clients de-risk drug development and reduce reliance on animal testing.

The CellOPTIQ® platform is an optical imaging-based assay that simultaneously measures voltage, calcium transients, and contractility in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in a single, medium-throughput experiment, providing integrated data on cardiac excitation-contraction coupling.

Total raised: $7.5M

Main competitors include specialty CROs (Ncardia, Axol Bioscience), instrument providers (CytoCypher, Molecular Devices), and large generalist CROs (Charles River, Labcorp). Clyde differentiates through its unique integrated 'three-in-one' CellOPTIQ assay, its validated status for the regulatory CiPA initiative, and its deep specialization in cardiac electrophysiology.